C. Calfa

发表

Development of a multigenerational digital lifestyle intervention for women cancer survivors and their families

Sara M. St. George, F. Penedo, J. Slingerland, 2020, Psycho-oncology.

Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2020, JCO precision oncology.

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

B. Necela, E. Perez, C. Calfa, 2018, Breast Cancer Research.

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, J. Krauss, C. Calfa, 2022, JCO precision oncology.

Ocular involvement as the initial manifestation of T-cell chronic lymphocytic leukemia.

I. Lossos, C. Calfa, P. Ruiz, 2007, American journal of ophthalmology.

[Histogenesis of squamous cell carcinoma of the gallbladder. An anatomo-clinical case].

C. Calfa, M. Cintorino, F. Cetta, 1981, Archivio "de Vecchi" per l'anatomia patologica e la medicina clinica.

Generation of adaptive HER2-specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831.

E. Perez, K. Ballman, C. Calfa, 2013 .

Improved Survival of HER2+ Breast Cancer Patients Treated with Trastuzumab and Chemotherapy Is Associated with Host Antibody Immunity against the HER2 Intracellular Domain.

E. Perez, E. Mittendorf, K. Ballman, 2016, Cancer research.

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Jennifer L. Caswell-Jin, A. Giuliano, C. Curtis, 2020, Nature Communications.

Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents

K. Webster, C. Calfa, J. Rosenblatt, 2006 .

Implementation and Feasibility of an Electronic Health Record–Integrated Patient-Reported Outcomes Symptom and Needs Monitoring Pilot in Ambulatory Oncology

F. Penedo, C. Calfa, M. Schlumbrecht, 2022, JCO oncology practice.

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, C. Calfa, E. Garrett-Mayer, 2020, Targeted Oncology.

Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

R. Schilsky, A. Alva, C. Calfa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.

C. Calfa, D. Shin, J. Rosenblatt, 2009, Cancer research.

Microenvironment and Immunology Delivery of NKG 2 D Ligand Using an Anti-HER 2 Antibody-NKG 2 D Ligand Fusion Protein Results in an Enhanced Innate and Adaptive Antitumor Response

C. Calfa, D. Shin, J. Rosenblatt, 2010 .

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer

B. Necela, E. Perez, C. Calfa, 2018, Breast cancer research : BCR.

Combination trastuzumab and chemotherapy to induce immunity to multiple tumor antigens in patients with HER2-positive metastatic breast cancer: NCCTG (Alliance) studies N0337 and N98-32-52.

E. Perez, K. Ballman, C. Calfa, 2013 .

Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

R. Schilsky, C. Calfa, F. Worden, 2021 .

Gemcitabine and oxaliplatin (GEMOX), a promissing combination for the treatment of relapsed, advanced or metastatic non small cell lung cancer (NSCLC)

C. Calfa, L. Raez, G. Lopes, 2008 .

Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, Rui Li, A. Alva, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Olaparib in Patients With Pancreatic Cancer With BRCA1/2 Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

R. Schilsky, A. Alva, C. Calfa, 2024, JCO Precision Oncology.

Pembrolizumab (P) in patients (pts) with metastatic breast cancer (MBC) with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

R. Schilsky, A. Alva, C. Calfa, 2019, Journal of Clinical Oncology.

Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, C. Calfa, K. Gogineni, 2024, JCO precision oncology.

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, F. Meric-Bernstam, M. von Mehren, 2023, JCO precision oncology.